Alexandria Co. For Pharmaceuticals & Chemical Industries (EGX:AXPH)
Egypt · Delayed Price · Currency is EGP 1,177.97
+11.75 (1.01%)
At close: May 13, 2026
EGX:AXPH Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 3,024 | 2,751 | 1,768 | 1,484 | 1,100 | 1,104 |
Other Revenue | -3.68 | - | - | - | 0 | - |
| 3,020 | 2,751 | 1,768 | 1,484 | 1,100 | 1,104 | |
Revenue Growth (YoY) | 29.25% | 55.56% | 19.12% | 34.94% | -0.38% | 7.75% |
Cost of Revenue | 2,253 | 2,092 | 1,373 | 1,223 | 876.78 | 841.45 |
Gross Profit | 767.03 | 658.95 | 395.18 | 260.89 | 223.24 | 262.8 |
Selling, General & Admin | 100.07 | 102.21 | 89.77 | 83.52 | 75.65 | 93.71 |
Other Operating Expenses | 41.53 | 52.04 | 37.92 | 22.44 | 13.05 | 14.98 |
Operating Expenses | 141.6 | 154.25 | 127.69 | 105.96 | 88.7 | 108.69 |
Operating Income | 625.43 | 504.7 | 267.49 | 154.92 | 134.54 | 154.11 |
Interest & Investment Income | 15.69 | 19.56 | 13.52 | 5.52 | 5.55 | 2.82 |
Currency Exchange Gain (Loss) | -3.37 | -3.01 | 8.03 | 11.57 | 4.4 | -0.24 |
Other Non Operating Income (Expenses) | - | - | 0 | 0 | - | 0 |
EBT Excluding Unusual Items | 637.75 | 521.25 | 289.04 | 172.02 | 144.49 | 156.69 |
Gain (Loss) on Sale of Assets | - | - | 0.56 | 1.03 | - | 0.4 |
Other Unusual Items | -16.84 | -12.34 | -7.57 | -8.1 | -0.99 | -5.5 |
Pretax Income | 620.9 | 508.9 | 282.03 | 164.95 | 143.5 | 151.59 |
Income Tax Expense | 126.86 | 117.74 | 65.35 | 38.52 | 26.08 | 34.59 |
Net Income | 494.04 | 391.17 | 216.68 | 126.43 | 117.42 | 117 |
Net Income to Common | 494.04 | 391.17 | 216.68 | 126.43 | 117.42 | 117 |
Net Income Growth | 61.46% | 80.53% | 71.39% | 7.67% | 0.36% | -31.20% |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 |
Shares Change (YoY) | - | - | - | - | - | -15.35% |
EPS (Basic) | 98.81 | 78.23 | 43.34 | 25.29 | 23.48 | 23.40 |
EPS (Diluted) | 98.81 | 78.23 | 43.34 | 25.29 | 23.48 | 23.40 |
EPS Growth | 61.46% | 80.53% | 71.39% | 7.67% | 0.36% | -18.73% |
Free Cash Flow | 292.1 | 306.27 | 127.41 | 7.09 | 160.9 | -20.57 |
Free Cash Flow Per Share | 58.42 | 61.25 | 25.48 | 1.42 | 32.18 | -4.11 |
Dividend Per Share | 62.950 | 62.950 | 30.000 | 13.000 | - | 10.000 |
Dividend Growth | 109.83% | 109.83% | 130.77% | - | - | -35.48% |
Gross Margin | 25.40% | 23.96% | 22.35% | 17.58% | 20.29% | 23.80% |
Operating Margin | 20.71% | 18.35% | 15.13% | 10.44% | 12.23% | 13.96% |
Profit Margin | 16.36% | 14.22% | 12.26% | 8.52% | 10.67% | 10.60% |
Free Cash Flow Margin | 9.67% | 11.13% | 7.21% | 0.48% | 14.63% | -1.86% |
EBITDA | 671.75 | 547.92 | 305.05 | 182.92 | 157.73 | 177.74 |
EBITDA Margin | 22.24% | 19.92% | 17.25% | 12.32% | 14.34% | 16.10% |
D&A For EBITDA | 46.32 | 43.22 | 37.56 | 28 | 23.18 | 23.63 |
EBIT | 625.43 | 504.7 | 267.49 | 154.92 | 134.54 | 154.11 |
EBIT Margin | 20.71% | 18.35% | 15.13% | 10.44% | 12.23% | 13.96% |
Effective Tax Rate | 20.43% | 23.14% | 23.17% | 23.35% | 18.17% | 22.82% |
Revenue as Reported | 3,031 | 2,762 | 1,777 | 1,486 | 1,101 | 1,111 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.